Form 4: CTNM CMO Exercises, Sells Shares, Receives New Options

Contineum Therapeutics' CMO and Head of Development, Tim Watkins, exercised stock options, sold shares, and was granted new options under a pre-arranged trading plan.

Summary

• Tim Watkins, CMO & Head of Development of Contineum Therapeutics, Inc. (CTNM), engaged in multiple transactions.
• On January 28, 2026, Watkins exercised stock options to acquire 3,611 shares of Class A Common Stock at an exercise price of $4.50 per share.
• Immediately following the exercise, Watkins sold 2,800 shares of Class A Common Stock at a weighted average price of $14.0861, with prices ranging from $13.44 to $14.39.
• Additionally, 811 shares of Class A Common Stock were sold at a weighted average price of $14.4848, with prices ranging from $14.45 to $14.53.
• These transactions on January 28, 2026, were conducted under a Rule 10b5-1 trading plan adopted on September 23, 2025.
• On January 30, 2026, Watkins was granted 160,000 new stock options under the Issuer's 2024 Equity Incentive Plan, with an exercise price of $14.26.
• These new options will vest in equal monthly installments over 48 months, contingent on continuous service.
• Following these transactions, Watkins beneficially owns 160,000 derivative securities (stock options) and 0 Class A Common Stock from the reported sales.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal due to the immediate sale of all exercised shares by a key executive, despite the concurrent grant of new options and the pre-arranged nature of the sales.

Positives

• Grant of 160,000 new stock options to the CMO, indicating continued incentive and alignment with company performance.
• The new options have a vesting schedule over 48 months, promoting long-term commitment.

Negatives

• The CMO sold all 3,611 shares acquired through option exercise, along with an additional 811 shares, totaling 3,611 shares sold. This represents a full liquidation of the exercised options.
• The sales occurred at prices significantly higher than the exercise price ($4.50), but the act of selling immediately after exercise can be perceived as a lack of conviction in the near-term stock price appreciation, despite being part of a 10b5-1 plan.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by the market as they can signal management's perception of the company's valuation. While these sales were pre-arranged under a 10b5-1 plan, the immediate sale of all exercised shares by a key executive like the CMO could be interpreted by some investors as a move to monetize gains rather than hold for future appreciation, even as new options are granted.

Comparison to Industry Standards

• StockSavvy.ai observes that 10b5-1 plans are a common mechanism for executives to manage their equity holdings while avoiding accusations of insider trading.
• The grant of new options alongside sales is also a standard practice in executive compensation, aiming to balance immediate liquidity needs with long-term incentive alignment.
• Without specific comparable executive compensation packages or trading patterns from peers in the biotechnology or pharmaceutical sector, a direct comparison of the scale of these transactions to industry benchmarks is limited.
• However, the exercise and immediate sale of options is a common strategy for executives to realize value from vested equity.

Related Party Transactions

• The transactions involve the CMO and Head of Development, Tim Watkins, exercising stock options and selling shares of Contineum Therapeutics, Inc., which constitutes a related party transaction as an insider dealing with company securities.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could lead to negative sentiment and potentially downward pressure on the stock price. The grant of new options, however, aligns the executive's long-term interests with shareholders.

Next Steps

• The remaining portion of previously held options will continue to vest in 36 equal monthly installments after October 28, 2025.
• The newly granted 160,000 stock options will vest in equal monthly installments over 48 months, subject to continuous service.

Key Dates

Recommendation

While the immediate sale of exercised options by the CMO could be a negative signal, the transactions were pre-planned under a 10b5-1 plan, mitigating some of the negative implications. Furthermore, the executive received a substantial grant of new options, indicating continued long-term alignment with the company. Given these mixed signals, a 'hold' recommendation is appropriate, advising investors to monitor future developments and broader company performance rather than making immediate buy or sell decisions based solely on this Form 4.

Keywords

Contineum Therapeutics, CTNM, Form 4, Insider Trading, Stock Options, Executive Compensation, Tim Watkins, CMO, Share Sale, Option Exercise, 10b5-1 Plan